跳到正文
原文
STAT 主站· Adam Feuerstein·· 29 天前精选AI 评分79

Moderna 与 Merck 个性化 mRNA 癌症疫苗 intismeran autogene 在黑色素瘤试验中达成关键终点

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

AI 导读

Moderna 与 Merck 合作开展的个性化 mRNA 癌症疫苗 intismeran autogene 在黑色素瘤大型临床试验中,使患者疾病复发风险降低 42%。该疫苗通过攻击肿瘤特有的新抗原发挥治疗作用,其疗效结果由两家公司发布,肿瘤学家认为这是黑色素瘤治疗的重要进展。

推荐理由

报道明确 intismeran autogene 在黑色素瘤试验中降低复发风险 42%,可作为评估个性化 mRNA 癌症疫苗疗效层级的参照。

正文 · 原文

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

MADRID — A personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatment, according to a large clinical trial conducted by the drugmakers Moderna and Merck.

The results are an important advance for the treatment of melanoma, oncologists said, because patients lived significantly longer without their cancer returning. 

The success of the Moderna-Merck vaccine, intismeran autogene, may also usher in a new wave of treatments for other types of cancer. It is an individualized therapy that attacks the unique mutations, called neoantigens, found in a patient’s tumor. The approach is made possible by the same mRNA technology that led to the rapid development of vaccines against Covid-19. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com